MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Longitudinal analysis of disease progression in a large PKAN cohort in the Dominican Republic

C. Muniz, S. Baser, R. Ericson, M. Santana Jimenez, C. Bass, F. Middleton (Santo Domingo, Dominican Republic)

Meeting: 2019 International Congress

Abstract Number: 531

Keywords: Pantothenate kinase-associated neurodegenetration(PKAN)

Session Information

Date: Monday, September 23, 2019

Session Title: Rare Genetic and Metabolic Diseases

Session Time: 1:45pm-3:15pm

Location: Les Muses Terrace, Level 3

Objective: To analyze the rate of disease progression of PKAN over a 12 year period in 37 patients with genetically-confirmed PKAN in the Dominican Republic.

Background: PKAN is a rare generalized dystonia with recessive inheritance that slowly and relentlessly progresses over time in otherwise developmentally normal children. Carriers of a c.680 A>G mutation of the PANK2 gene are highly prevalent in the Dominican Republic allowing longitudinal follow-up and characterization of the natural course of the disease in a large cohort. Significant phenotypic expression has been observed with varying rates of severity and disease progression, making characterization of said rates relevant for treatment and prognosis.

Method: All patients with genetically-confirmed PKAN and at least two standardized measurements of dystonia severity between the years of 2007-2019 were selected. The rate of disease progression for each patient was calculated by subtracting consecutive score measurements and dividing the result by the time intervals between each measurement. To control for the effects of repeated, correlated, measurements in the same subjects over time and the effects of phenotypic variation between subjects, linear mixed effect model (LMM) was used, with random intercepts and slopes. Estimates were made by restricted maximum likelihood (REML) with an autoregressive (heterogeneous) covariance structure.

Results: Two or more standardized scores with the Fahn-Mardsen (FM) and/or the Unified Dystonia Rating Scale (UDRS) were available for 37 patients at any of four time points (2007, 2010, 2011 and 2019) yielding a total of 105 rated scales and a cumulative measured duration of disease of 307 years. The mean age of onset and duration of disease per subject were 9.7 ± 2.7 and 15.6 ± 9, respectively. The number of valid intervals of the UDRS were 30 with a mean difference of 52.17 ± 29 and of the FM 32 with a mean difference of 34.28 ± 32.4. The average rate of disease progression as assessed by the UDRS was 13.3 points per year and by the FM 15.5 per year.

Conclusion: Based on longitudinal measurements with standardized instruments, the average rate of progression of PKAN in the Dominican Republic is 13.3 and 15.5 points per year on the UDRS and FM, respectively.

To cite this abstract in AMA style:

C. Muniz, S. Baser, R. Ericson, M. Santana Jimenez, C. Bass, F. Middleton. Longitudinal analysis of disease progression in a large PKAN cohort in the Dominican Republic [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/longitudinal-analysis-of-disease-progression-in-a-large-pkan-cohort-in-the-dominican-republic/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/longitudinal-analysis-of-disease-progression-in-a-large-pkan-cohort-in-the-dominican-republic/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley